Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

Mindray (300760) Q3 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

Q3 2025 earnings summary

30 Oct, 2025

Executive summary

  • Q3 revenue reached ¥9.09 billion, up 1.53% year-over-year, marking a turnaround after previous declines.

  • Net profit attributable to shareholders for Q3 was ¥2.50 billion, down 18.69% year-over-year; YTD net profit fell 28.83%.

  • International business in Q3 grew 11.93% year-over-year, with Europe exceeding 20% growth and strong double-digit gains in CIS and Middle East/Africa.

  • R&D investment for the first three quarters was ¥2.69 billion, 10.4% of revenue, with continued product innovation and patent growth.

Financial highlights

  • YTD revenue was ¥25.83 billion, down 12.38% year-over-year.

  • YTD net profit attributable to shareholders was ¥7.57 billion, down 28.83% year-over-year.

  • Operating cash flow for Q3 was ¥7.27 billion, down 34.32% year-over-year, mainly due to reduced cash from sales and services.

  • Basic EPS for Q3 was ¥2.0641, down 18.62% year-over-year; YTD basic EPS was ¥6.2481, down 28.84%.

  • Total assets at Q3-end were ¥59.27 billion, up 4.63% from year-end; equity attributable to shareholders was ¥39.30 billion, up 9.60%.

Outlook and guidance

  • Q4 revenue growth is expected to accelerate compared to Q3, with international business momentum and ongoing global supply chain and localization efforts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more